For tumor (sub)types with a high prevalence of NTRK fusions, including MSI-H/dMMR, BRAF and RAS wildtype mCRC, upfront testing with RNA-NGS, FFPE-TLC, or qRT-PCR could be a reasonable approach. The gene discussed is BRAF; the disease is neoplasm.